Vivos Inc. Certifies University of Florida Veterinary Hospital for IsoPet® Precision Radionuclide Therapy™
Rhea-AI Summary
Vivos Inc. (OTCQB: RDGL) has announced the certification of the University of Florida Veterinary Hospital to offer IsoPet® Precision Radionuclide Therapy™, a targeted cancer treatment for animals. This innovative therapy uses a proprietary radionuclide injection to treat solid tumors in pets, offering a minimally invasive alternative to traditional treatments.
The certification marks an expansion in Vivos' network of certified clinics, with the company providing comprehensive support through the licensing process and training to ensure safe and effective administration of IsoPet therapy. Additional veterinary hospitals are currently in the certification pipeline as part of the company's growth strategy.
Positive
- Expansion of treatment network through certification of a major veterinary institution
- Strategic growth in clinic network indicates business development progress
- Establishment of presence in academic medical setting adds credibility
Negative
- Limited current network size suggests early stage of commercialization
- Regulatory and licensing requirements may slow expansion pace
News Market Reaction 1 Alert
On the day this news was published, RDGL declined 0.51%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Kennewick, WA, May 15, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) today announced that the University of Florida Veterinary Hospital has been certified to offer IsoPet® Precision Radionuclide Therapy™—a breakthrough cancer treatment for animals.
The University of Florida Veterinary Hospital, a leader in advanced veterinary care and research, is now licensed and equipped to deliver IsoPet® therapy as part of its oncology services. This certification expands the availability of a targeted, minimally invasive cancer treatment that uses a proprietary radionuclide injection to treat solid tumors in pets.
“Our goal is to grow the network of certified clinics offering IsoPet therapy across the country,” said Dr. Michael Korenko, President and CEO of Vivos Inc. “Each certification represents a step toward broader access to a treatment that is both effective and far less invasive than traditional options. The University of Florida team has demonstrated the clinical rigor and enthusiasm needed to offer this innovative therapy.”
Vivos supports each clinic through the licensing process, provides training to ensure each facility is fully prepared to administer IsoPet safely and effectively. Additional veterinary hospitals are currently undergoing the certification process.
Michael K. Korenko, Sc.D.
President & CEO, Vivos Inc.
Email: MKorenko@RadioGel.com
Follow Vivos Inc. on X (Twitter): @VivosIncUSA
Learn more about RadioGel® and IsoPet® at www.VivosInc.com
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, identified by terms such as “will,” “expects,” “plans,” “anticipates,” and “intends.” These statements involve risks and uncertainties that may cause actual results to differ materially, including challenges in executing business strategies, economic conditions, competition, regulatory changes, delays in clinic certifications, and other factors beyond Vivos Inc.’s control. For a detailed discussion of these risks, refer to the company’s filings with the Securities and Exchange Commission.
FAQ
What is IsoPet Precision Radionuclide Therapy offered by Vivos (RDGL)?
Which new facility has been certified to offer Vivos' (RDGL) IsoPet therapy in 2025?
How does Vivos (RDGL) support clinics in offering IsoPet therapy?
What is Vivos' (RDGL) strategy for expanding IsoPet therapy availability?
